Daniela Bazan

Daniela Bazan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in Cureus
Verified
Journal Article
Open access
MHMichael Horseman
Michael Horseman
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
ATAndrew S. Tenpas
Andrew S. Tenpas
RJRene Verduzco Jr.
Rene Verduzco Jr.
Salim SuraniSalim Surani
Salim Surani
Humans maintain core body temperature via a complicated system of physiologic mechanisms that counteract heat/cold fluctuations from metabolism, exertion, and the environment. Overextension of these mechanisms or disruption of body temperature homeostasis leads to bodily dysfunction, culminating in a syndrome analogous to exertional heat stroke (EHS). The inability of this thermoregulatory process to maintain the body temperature is caused by either thermal stress or certain drugs. EHS is a syndrome characterized by hyperthermia and the activation of systemic inflammation. Several drug-induced hyperthermic syndromes may resemble EHS and share common mechanisms. The purpose of this article is to review the current literature and compare exertional heat stroke (EHS) to three of the most widely studied drug-induced hyperthermic syndromes: malignant hyperthermia (MH), neuroleptic malignant syndrome (NMS), and serotonin syndrome (SS). Drugs and drug classes that have been implicated in these conditions include amphetamines, diuretics, cocaine, antipsychotics, metoclopramide, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and many more. Observations suggest that severe or fulminant cases of drug-induced hyperthermia may evolve into an inflammatory syndrome best described as heat stroke. Their underlying mechanisms, symptoms, and treatment approaches will be reviewed to assist in accurate diagnosis, which will impact the management of potentially life-threatening complications.

26 January 2021 in Medicina
Verified
Journal Article
Open access
PDF file
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
MHMichael Horseman
Michael Horseman
JWJaye Weston
Jaye Weston
NSNephy Samuel
Nephy Samuel
DBDaniela Bazan
Daniela Bazan
Traditionally, the management of patients with pulmonary embolism has been accomplished with anticoagulant treatment with parenteral heparins and oral vitamin K antagonists. Although the administration of heparins and oral vitamin K antagonists still plays a role in pulmonary embolism management, the use of these therapies are limited due to other options now available. This is due to their toxicity profile, clearance limitations, and many interactions with other medications and nutrients. The emergence of direct oral anticoagulation therapies has led to more options now being available to manage pulmonary embolism in inpatient and outpatient settings conveniently. These oral therapeutic options have opened up opportunities for safe and effective pulmonary embolism management, as more evidence and research is now available about reversal agents and monitoring parameters. The evolution of the pharmacological management of pulmonary embolism has provided us with better understanding regarding the selection of anticoagulants. There is also a better understanding and employment of anticoagulants in pulmonary embolism in special populations, such as patients with liver failure, renal failure, malignancy, and COVID-19.

23 May 2025 in Cureus
Verified
Journal Article
Open access
PDF file
DBDaniela Bazan
Daniela Bazan
LELauren Esqueda
Lauren Esqueda
AIAshly Ibrahim
Ashly Ibrahim
LGLorena Gonzalez
Lorena Gonzalez
JSJeffrey J. Skubic
Jeffrey J. Skubic
RVRene Verduzco
Rene Verduzco
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of commonly prescribed medications used in diabetes management for both their cardiovascular and renal benefits. However, as a class, SGLT2 inhibitors have a known side effect risk for ketoacidosis, including the rarer version called euglycemic diabetic ketoacidosis (DKA). We present three cases of euglycemic DKA postoperatively, in patients who were on SGLT2 inhibitors for type 2 diabetes mellitus. A DKA protocol was initiated for all three patients, and after treatment with fluid and insulin therapy, all patients recovered. All three were restarted on their SGLT2 inhibitor upon discharge. Based on this limited experience, we recommend close monitoring of postoperative patients on SGLT2 inhibitors to allow early detection of euglycemic DKA. Larger trials are needed to determine the exact, optimal timing of restarting SGLT2 inhibitors postoperatively.